Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Shashank J Patel"'
Autor:
Kendra A Williams, Minnkyong Lee, Ying Hu, Jonathan Andreas, Shashank J Patel, Suiyuan Zhang, Peter Chines, Abdel Elkahloun, Settara Chandrasekharappa, J Silvio Gutkind, Alfredo A Molinolo, Nigel P S Crawford
Publikováno v:
PLoS Genetics, Vol 10, Iss 11, p e1004809 (2014)
Although prostate cancer typically runs an indolent course, a subset of men develop aggressive, fatal forms of this disease. We hypothesize that germline variation modulates susceptibility to aggressive prostate cancer. The goal of this work is to id
Externí odkaz:
https://doaj.org/article/37dcb56c93a64c16bce461847a4a366a
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61848 (2013)
Neuroendocrine (NE) differentiation has gained increased attention as a prostate cancer (PC) prognostic marker. The aim of this study is to determine whether host germline genetic variation influences tumor progression and metastasis in C57BL/6-Tg(TR
Externí odkaz:
https://doaj.org/article/98df94023eb24663a41da0fd4f7b9870
Autor:
Rustin R. Lovewell, Junshik Hong, Subhadip Kundu, Carly M. Fielder, Qianni Hu, Kwang Woon Kim, Haley E. Ramsey, Agnieszka E. Gorska, Londa S. Fuller, Linjie Tian, Priyanka Kothari, Ana Paucarmayta, Emily F. Mason, Ingrid Meza, Yanira Manzanarez, Jason Bosiacki, Karla Maloveste, Ngan Mitchell, Emilia A. Barbu, Aaron Morawski, Sebastien Maloveste, Zac Cusumano, Shashank J. Patel, Michael R. Savona, Solomon Langermann, Han Myint, Dallas B. Flies, Tae Kon Kim
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remain
Externí odkaz:
https://doaj.org/article/4400206aba4d473a88839c90e119c65a
Autor:
Rigel J. Kishton, Shashank J. Patel, Amy E. Decker, Suman K. Vodnala, Maggie Cam, Tori N. Yamamoto, Yogin Patel, Madhusudhanan Sukumar, Zhiya Yu, Michelle Ji, Amanda N. Henning, Devikala Gurusamy, Douglas C. Palmer, Roxana A. Stefanescu, Andrew T. Girvin, Winifred Lo, Anna Pasetto, Parisa Malekzadeh, Drew C. Deniger, Kris C. Wood, Neville E. Sanjana, Nicholas P. Restifo
Publikováno v:
Cell reports. 40(5)
Adoptive T cell therapies (ACT) have been curative for a limited number of cancer patients. The sensitization of cancer cells to T cell killing may expand the benefit of these therapies for more patients. To this end, we use a three-step approach to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15d1bd3b365805ffc9eeede241fe3495
https://pubmed.ncbi.nlm.nih.gov/35926468
https://pubmed.ncbi.nlm.nih.gov/35926468
Autor:
Douglas C, Palmer, Beau R, Webber, Yogin, Patel, Matthew J, Johnson, Christine M, Kariya, Walker S, Lahr, Maria R, Parkhurst, Jared J, Gartner, Todd D, Prickett, Frank J, Lowery, Rigel J, Kishton, Devikala, Gurusamy, Zulmarie, Franco, Suman K, Vodnala, Miechaleen D, Diers, Natalie K, Wolf, Nicholas J, Slipek, David H, McKenna, Darin, Sumstad, Lydia, Viney, Tom, Henley, Tilmann, Bürckstümmer, Oliver, Baker, Ying, Hu, Chunhua, Yan, Daoud, Meerzaman, Kartik, Padhan, Winnie, Lo, Parisa, Malekzadeh, Li, Jia, Drew C, Deniger, Shashank J, Patel, Paul F, Robbins, R Scott, McIvor, Modassir, Choudhry, Steven A, Rosenberg, Branden S, Moriarity, Nicholas P, Restifo
Publikováno v:
Med. 3:682-704.e8
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) fails to consistently elicit tumor rejection. Manipulation of intrinsic factors that inhibit T cell effector function and neoantigen recognition may therefore improve TIL therapy outcomes. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2493e0ebec169c9a2ac88f6a46b00bbc
https://doi.org/10.1016/j.medj.2022.07.008
https://doi.org/10.1016/j.medj.2022.07.008
Autor:
Matthew D. Johnson, Ying Hu, Winnie Lo, Todd D. Prickett, Douglas C. Palmer, Steven A. Rosenberg, R. Scott McIvor, Daoud Meerzaman, Li Jia, Frank J. Lowery, Parisa Malekzadeh, Walker S. Lahr, Modassir Choudhry, Tilmann Bürckstümmer, Maria R. Parkhurst, Rigel J. Kishton, Nicholas P. Restifo, Tom Henley, David H. McKenna, Devikala Gurusamy, Darin Sumstad, Chunhua Yan, Miechaleen D. Diers, Suman K. Vodnala, Branden S. Moriarity, Zulmarie Franco, Lydia Viney, Christine M. Kariya, Kartik Padhan, Yogin Patel, Natalie K. Wolf, Paul D. Robbins, Beau R. Webber, Jared J. Gartner, Drew C. Deniger, Oliver Baker, Nicholas J. Slipek, Shashank J. Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoantigen-specific T cells isolated from tumors have shown promise clinically but fail to consistently elicit durable tumor regression. Expression of the intracellular checkpoint CISH is elevated in human tumor infiltrating lymphocytes (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b30a2ebb661239363462a7e79ab7236
https://doi.org/10.1136/jitc-2020-sitc2020.0333
https://doi.org/10.1136/jitc-2020-sitc2020.0333
Autor:
Modassir Choudhry, Miechaleen D. Diers, Nicholas P. Restifo, Tom Henley, Natalie K. Wolf, Rigel J. Kishton, Paul F. Robbins, Yogin Patel, Lydia Viney, Winnie Lo, Steven A. Rosenberg, Branden S. Moriarity, Tilmann Bürckstümmer, Maria R. Parkhurst, Christine M. Kariya, Parisa Malekzadeh, David H. McKenna, Devikala Gurusamy, Darin Sumstad, Chunhua Yan, Zulmarie Franco, Frank J. Lowery, Douglas C. Palmer, R. Scott McIvor, Daoud Meerzaman, Todd D. Prickett, Matthew Johnson, Ying Hu, Suman K. Vodnala, Nicholas J. Slipek, Shashank J. Patel, Oliver Baker, Li Jia, Drew C. Deniger, Kartik Padhan, Beau R. Webber, Walker S. Lahr, Jared J. Gartner
While neoantigen-specific tumor infiltrating lymphocytes (TIL) can be derived from in antigen-expressing tumors, their adoptive transfer fails to consistently elicit durable tumor regression. There has been much focus on the role of activation/exhaus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00218cdfa78254998d1e8cb891dc1886
https://doi.org/10.1101/2020.09.24.306571
https://doi.org/10.1101/2020.09.24.306571
Autor:
Drew C. Deniger, Rigel J. Kishton, Frank J. Lowery, Ying Hu, Tilmann Bürckstümmer, Yogin Patel, Modassir Choudhry, Matthew D. Johnson, Natalie K. Wolf, Kartik Padhan, Beau R. Webber, Parisa Malekzadeh, David H. McKenna, Paul D. Robbins, Nicholas P. Restifo, Devikala Gurusamy, Steven A. Rosenberg, Tom Henley, Darin Sumstad, Maria R. Parkhurst, Chunhua Yan, Li Jia, Winifred Lo, Zulmarie Franco, Nicholas J. Slipek, R. Scott McIvor, Shashank J. Patel, Oliver Baker, Todd D. Prickett, Lydia Viney, Jared J. Gartner, Suman K. Vodnala, Miechaleen D. Diers, Walker S. Lahr, Douglas C. Palmer, Daoud Meerzaman, Branden S. Moriarity, Christine M. Kariya
Publikováno v:
SSRN Electronic Journal.
While neoantigen-specific tumor infiltrating lymphocytes (TIL) can be derived from in antigen-expressing tumors, their adoptive transfer fails to consistently elicit durable tumor regression. There has been much focus on the role of activation/exhaus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd11f4a0565c0d382f87a456e33aaf1
https://doi.org/10.2139/ssrn.3751760
https://doi.org/10.2139/ssrn.3751760
Autor:
Tori N. Yamamoto, Nicholas P. Restifo, Devikala Gurusamy, Zhiya Yu, Amy K Decker, Rigel J. Kishton, Parisa Malekzadeh, Suman K. Vodnala, Drew C. Deniger, Madhusudhanan Sukumar, Douglas C. Palmer, Yogin Patel, Neville E. Sanjana, Michelle Ji, Winifred Lo, Kris C. Wood, Amanda N. Henning, Shashank J. Patel, Anna Pasetto
SummaryAll current highly effective anti-tumor immunotherapeutics depend on the activity of T cells, but tumor cells can escape immune recognition by several mechanisms including loss of function in antigen presentation and inflammatory response gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22b01f07738945d244232c88d5cf0fb9
Autor:
Christine M. Kariya, Li Jia, Tori N. Yamamoto, Shashank J. Patel, Devikala Gurusamy, Sri Krishna, Zhiya Yu, Arash Eidizadeh, Madhusudhanan Sukumar, Amanda N. Henning, Nicholas P. Restifo, Mary A. Black, Nikolaos Zacharakis, Jenny H. Pan, Suman K. Vodnala, Douglas C. Palmer, Robert L. Eil, Rigel J. Kishton
Publikováno v:
Cancer cell. 37(6)
Summary T cells are central to all currently effective cancer immunotherapies, but the characteristics defining therapeutically effective anti-tumor T cells have not been comprehensively elucidated. Here, we delineate four phenotypic qualities of eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2c40dbd689b881b667052bbde33208c
https://pubmed.ncbi.nlm.nih.gov/32516586
https://pubmed.ncbi.nlm.nih.gov/32516586